Details of the Drug

General Information of Drug (ID: DM0BL2G)

Drug Name
Mitiperstat
Synonyms
Mitiperstat; AZD4831; Mitiperstat [INN]; AZD-4831; S6GYK3X4QQ; 1933460-19-5; UNII-S6GYK3X4QQ; AZD-4831 [WHO-DD]; 1-((2-((1R)-1-Aminoethyl)-4-chloro-phenyl)methyl)-2-thioxo-5hpyrrolo(3,2-d)pyrimidin-4-one; 4H-Pyrrolo(3,2-d)pyrimidin-4-one, 1-((2-((1R)-1-aminoethyl)-4-chlorophenyl)methyl)-1,2,3,5-tetrahydro-2-thioxo-; 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-1,2,3,5-tetrahydro-2-thioxo-; Alternative Preparation; MITIPERSTAT [USAN]; Azd 4831; CHEMBL5095218; SCHEMBL17782047; GTPL12154; AZD 4831 [WHO-DD]; BHKKSKOHRFHHIN-MRVPVSSYSA-N; BDBM312172; GLXC-26157; EX-A7129; compound 16 [PMID: 36005476]; HY-145581; CS-0376445; US9616063, 3; 1-({2-[(1R)-1-aminoethyl]-4-chlorophenyl}methyl)-2-sulfanylidene-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; 1-({2-[(1R)-1-aminoethyl]-4-chlorophenyl}methyl)-2-sulfanylidene-1H,2H,3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one; 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one; 1-{2-[(1R)-1-Aminoethyl]-4-chlorobenzyl}-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one
Indication
Disease Entry ICD 11 Status REF
Heart failure with preserved ejection fraction BD11.0 Phase 2/3 [1]
Chronic obstructive pulmonary disease CA22 Phase 2 [2]
Drug Type
Small molecule
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C15H15ClN4OS
Canonical SMILES
CC(C1=C(C=CC(=C1)Cl)CN2C3=C(C(=O)NC2=S)NC=C3)N
InChI
InChI=1S/C15H15ClN4OS/c1-8(17)11-6-10(16)3-2-9(11)7-20-12-4-5-18-13(12)14(21)19-15(20)22/h2-6,8,18H,7,17H2,1H3,(H,19,21,22)/t8-/m1/s1
InChIKey
BHKKSKOHRFHHIN-MRVPVSSYSA-N
Cross-matching ID
PubChem CID
121362450
TTD ID
D87IQS
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Myeloperoxidase (MPO) TTVCZPI PERM_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Heart failure with preserved ejection fraction
ICD Disease Classification BD11.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Myeloperoxidase (MPO) DTT MPO 2.88E-01 -0.02 -0.16
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04986202) A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for Up to 48 Weeks in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05492877) A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of Mitiperstat (AZD4831), for 12-24 Weeks, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
3 Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction. J Med Chem. 2022 Sep 8;65(17):11485-11496.